NO20015506D0 - Rekombinant humant mannanbindende lectin - Google Patents

Rekombinant humant mannanbindende lectin

Info

Publication number
NO20015506D0
NO20015506D0 NO20015506A NO20015506A NO20015506D0 NO 20015506 D0 NO20015506 D0 NO 20015506D0 NO 20015506 A NO20015506 A NO 20015506A NO 20015506 A NO20015506 A NO 20015506A NO 20015506 D0 NO20015506 D0 NO 20015506D0
Authority
NO
Norway
Prior art keywords
treatment
prophylaxis
binding lectin
mbl
infection
Prior art date
Application number
NO20015506A
Other languages
English (en)
Other versions
NO20015506L (no
Inventor
Steffen Thiel
Jens Christian Jensenius
Thomas Vorup Jensen
Original Assignee
Thomas Vorup Jensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Vorup Jensen filed Critical Thomas Vorup Jensen
Publication of NO20015506D0 publication Critical patent/NO20015506D0/no
Publication of NO20015506L publication Critical patent/NO20015506L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Filtering Materials (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
NO20015506A 1999-05-14 2001-11-09 Rekombinant humant mannanbindende lectin NO20015506L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900668 1999-05-14
DKPA199901508 1999-10-20
PCT/DK2000/000246 WO2000070043A1 (en) 1999-05-14 2000-05-10 Recombinant human mannan-binding lectin

Publications (2)

Publication Number Publication Date
NO20015506D0 true NO20015506D0 (no) 2001-11-09
NO20015506L NO20015506L (no) 2002-01-09

Family

ID=26064419

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20015481A NO20015481L (no) 1999-05-14 2001-11-08 Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer
NO20015506A NO20015506L (no) 1999-05-14 2001-11-09 Rekombinant humant mannanbindende lectin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20015481A NO20015481L (no) 1999-05-14 2001-11-08 Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer

Country Status (15)

Country Link
US (5) US6846649B1 (no)
EP (3) EP1181038B1 (no)
JP (2) JP2002544286A (no)
CN (2) CN1359420A (no)
AT (3) ATE336260T1 (no)
AU (2) AU781135B2 (no)
CA (2) CA2372435A1 (no)
DE (3) DE60030173T2 (no)
DK (3) DK1181038T3 (no)
ES (3) ES2281341T3 (no)
NO (2) NO20015481L (no)
NZ (2) NZ515717A (no)
PT (3) PT1402897E (no)
RU (2) RU2292217C2 (no)
WO (2) WO2000070043A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
DK1181038T3 (da) * 1999-05-14 2004-08-09 Steffen Thiel Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer
EP1303288A1 (en) * 2000-07-13 2003-04-23 Natimmune A/S Mannan-binding lectin (mbl) treatment of infections in individuals treated with tnf-alfa inhibitors
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
CN1487839A (zh) * 2000-11-27 2004-04-07 ղ˹��C��ղ˹���˹ 用作佐剂的集合素
WO2003010188A1 (en) 2001-07-23 2003-02-06 Natimmune A/S Production of high molecular mass lectins
WO2003018617A1 (fr) * 2001-08-31 2003-03-06 Fuso Pharmaceutical Industries, Ltd. Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain
DE60207678T2 (de) * 2001-10-19 2006-08-24 Natimmune A/S Isolierung von lectinen
ATE337014T1 (de) * 2002-03-15 2006-09-15 Natimmune As Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
EP1501537A4 (en) * 2002-04-24 2008-01-16 Queensland Inst Med Res MANNOSE BINDING LECTIN AND ITS USES
AU2003246119B2 (en) * 2002-06-28 2008-02-21 Fuso Pharmaceutical Industries, Ltd. Anti-HIV agent
ATE349538T1 (de) * 2002-09-10 2007-01-15 Natlmmune As Collectin-komplement aktivierende proteinchimären
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
JP2007525232A (ja) 2003-01-17 2007-09-06 イースロン メディカル インコーポレイテッド レクチンアフィニティー血液透析による血液のウイルス除去方法
PT2374819T (pt) 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US7135338B2 (en) * 2003-06-11 2006-11-14 Dobeel Corporation Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
DE20317914U1 (de) 2003-11-19 2004-12-30 Weh, Erwin Betätigungsvorrichtung für eine Schnellanschlusskupplung
US7335633B2 (en) 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
JP4884367B2 (ja) * 2004-02-24 2012-02-29 アボット・ヘルスケア・プロダクツ・ベスローテン・フェンノートシャップ 神経疾患を発症する危険性を決定するための方法
EP1730176A2 (en) * 2004-03-09 2006-12-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mvl, an antiviral protein from a cyanobacterium
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
US20090247454A1 (en) * 2004-09-29 2009-10-01 Mellitus, S.L. Method for detecting a predisposition to develop gestational diabetes mellitus and treatment for this disease
DE602005026705D1 (de) * 2004-12-23 2011-04-14 Council Scient Ind Res Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
US20080214435A1 (en) * 2005-04-11 2008-09-04 Natlmmune A/S Novel Cancer Indications of Mannan-Binding Lectin (Mbl) in the Treatment of Immunocompromised Individuals
WO2007044642A2 (en) 2005-10-06 2007-04-19 President And Fellows Of Harvard College And Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070226567A1 (en) * 2006-03-23 2007-09-27 Gorman Kevin W High speed bist utilizing clock multiplication
CN101939531A (zh) * 2008-01-16 2011-01-05 苏佩尔帕尔汽车工业和贸易有限公司 用于重型发动机平台的电动燃料泵
WO2009126346A2 (en) * 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
WO2010123594A2 (en) 2009-01-15 2010-10-28 Children's Medical Center Corporation Device for filtration of fluids there through and accompanying method
CA2787376A1 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
WO2011100528A2 (en) 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
CA2865744A1 (en) 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
WO2014014788A2 (en) 2012-07-18 2014-01-23 President And Fellows Of Harvard College Modification of surfaces for simulataneous repellency and targeted binding of desired moieties
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
EP3010522B1 (en) 2013-05-21 2021-01-20 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
US11919971B2 (en) 2016-05-16 2024-03-05 President And Fellows Of Harvard College Aqueous biomolecule coupling on CO2-plasma-activated surfaces
CN107050427A (zh) * 2017-02-27 2017-08-18 新乡医学院 MBL在制备预防或治疗以Tregs为靶点的疾病药物中的应用
CN107050436B (zh) * 2017-02-27 2020-03-17 新乡医学院 Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
WO2019110706A1 (en) * 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
RU2739113C1 (ru) * 2019-10-04 2020-12-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) Способ определения активности маннан-связывающих лектин-ассоциированных сериновых протеаз в тесте коагуляции фибриногена
WO2023087090A1 (en) * 2021-11-18 2023-05-25 Magellan Therapeutics Inc. Recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
DE3856180T2 (de) * 1987-08-20 1998-09-03 Childrens Medical Center Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
WO1997007210A1 (fr) 1995-08-17 1997-02-27 Fuso Pharmaceutical Industries, Ltd. Conglutinine recombinee et son procede de production
EP1008351B1 (en) 1997-08-21 2006-11-15 Takara Bio Inc. Carcinostatic agents
DK1084143T3 (da) * 1998-06-10 2006-12-27 Statens Seruminstitut Oprensningsproces til fremstilling af mannanbindende lectin og et medicinsk MBL-produkt
DK1181038T3 (da) * 1999-05-14 2004-08-09 Steffen Thiel Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer

Also Published As

Publication number Publication date
WO2000070043A1 (en) 2000-11-23
DE60030173D1 (de) 2006-09-28
DK1181038T3 (da) 2004-08-09
US20030191052A1 (en) 2003-10-09
US6562784B1 (en) 2003-05-13
DK1402897T3 (da) 2006-12-27
DE60030173T2 (de) 2007-08-23
CN1359420A (zh) 2002-07-17
EP1181038A2 (en) 2002-02-27
ES2219336T3 (es) 2004-12-01
AU4393500A (en) 2000-12-05
AU4393600A (en) 2000-12-05
EP1402897B1 (en) 2006-08-16
EP1181038B1 (en) 2004-04-14
EP1181363B1 (en) 2007-01-24
PT1181038E (pt) 2004-08-31
US7439224B2 (en) 2008-10-21
RU2005125625A (ru) 2007-02-20
JP2002543837A (ja) 2002-12-24
PT1181363E (pt) 2007-05-31
CN1359298A (zh) 2002-07-17
DE60033147D1 (de) 2007-03-15
CA2372435A1 (en) 2000-11-23
RU2292217C2 (ru) 2007-01-27
NO20015481L (no) 2002-01-11
CA2372128A1 (en) 2000-11-23
ATE264111T1 (de) 2004-04-15
DK1181363T3 (da) 2007-05-29
AU781135B2 (en) 2005-05-05
EP1402897A2 (en) 2004-03-31
WO2000069894A3 (en) 2001-02-08
ES2281341T3 (es) 2007-10-01
ES2271468T3 (es) 2007-04-16
US20040229212A1 (en) 2004-11-18
ATE352620T1 (de) 2007-02-15
NZ515717A (en) 2004-01-30
WO2000069894A2 (en) 2000-11-23
ATE336260T1 (de) 2006-09-15
US20070197428A1 (en) 2007-08-23
PT1402897E (pt) 2007-01-31
DE60009896D1 (de) 2004-05-19
EP1181363A1 (en) 2002-02-27
NZ515718A (en) 2004-03-26
EP1402897A3 (en) 2004-06-30
US7202207B2 (en) 2007-04-10
DE60033147T2 (de) 2007-12-13
DE60009896T2 (de) 2005-04-21
NO20015506L (no) 2002-01-09
AU779404B2 (en) 2005-01-20
NO20015481D0 (no) 2001-11-08
US6846649B1 (en) 2005-01-25
JP2002544286A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
DK1181363T3 (da) Rekombinant humant mannanbindende lectin
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
MY106315A (en) Pharmaceutical agents
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
WO2001011048A3 (en) Therapeutic polypeptides and methods for using same
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
MA27998A1 (fr) Nouvelle formulation
EP1040830A4 (en) REMEDY FOR NEURODEGENERATIVE DISEASES
DE69233108D1 (de) Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
DK1095061T3 (da) Peptider baseret på sekvensen af humant lactoferring og deres anvendelse
DE60231131D1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
FR2857597B1 (fr) Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie.
BR0210910A (pt) Derivados de imidazotriazinonas e sua aplicação contra processos inflamatórios e/ou doenças imunes
WO2002090552A3 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
FR2710844B1 (fr) Composition pour le traitement ou la prévention de l'herpès.
NZ228068A (en) Brominated or chlorinated allylamines and their pharmaceutical compositions
SI1173194T1 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
MD980129A (en) Antiherpetic remedy
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
WO2002097075A3 (en) Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties
HUP0402645A2 (hu) Egy glitazont és egy 4-oxobutánsavat tartalmazó gyógyászati készítmény és ennek alkalmazása cukorbetegség kezelésére
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application